In a more recent study on patients with PSP of various clinical phenotypes, Whitwell et al. (19) found that flortaucipir uptake was correlated with areas of expected involvement and MRI volume loss and in some autopsied cases with postmortem tau burden. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.